Daihan Pharmaceutical Co.,Ltd. (KOSDAQ:023910)
South Korea · Delayed Price · Currency is KRW 26,650
-100 (-0.37%)
Sep 11, 2026, 3:30 PM KST
Daihan Pharmaceutical Revenue
Daihan Pharmaceutical had revenue of 56.61B KRW in the quarter ending June 30, 2026, with 9.93% growth. This brings the company's revenue in the last twelve months to 216.55B, up 4.27% year-over-year. In the year 2025, Daihan Pharmaceutical had annual revenue of 208.61B with 2.16% growth.
Revenue (ttm)
216.55B
Revenue Growth
+4.27%
P/S Ratio
0.72
Revenue / Employee
391.60M
Employees
553
Market Cap
156.70B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 208.61B | 4.42B | 2.16% |
| Dec 31, 2024 | 204.19B | 8.28B | 4.23% |
| Dec 31, 2023 | 195.91B | 11.64B | 6.32% |
| Dec 31, 2022 | 184.27B | 12.80B | 7.47% |
| Dec 31, 2021 | 171.46B | 5.38B | 3.24% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chong Kun Dang Holdings | 961.64B |
| Daewon Pharmaceutical | 614.64B |
| Jeil Pharmaceutical Co.,Ltd | 543.49B |
| Dongwha Pharm.Co.,Ltd | 513.24B |
| Ilyang Pharmaceutical Co.,Ltd | 277.96B |
| JW Lifescience | 253.71B |
| Samil Pharmaceutical Co.,Ltd | 207.33B |
| Hana Pharm | 139.33B |